Tesamorelin: Mechanism, Research & UK Safety Profile
Also known as: Egrifta, TH9507, GHRH(1-44) analogue, Trans-3-hexenoic acid GHRH analogue
A synthetic analogue of growth hormone-releasing hormone (GHRH) developed by Theratechnologies, established in clinical research for visceral adiposity reduction in HIV-associated lipodystrophy, now investigated as a broader metabolic research compound.
Molecular formula
C₂₂₁H₃₆₆N₆₆O₆₇S
Molecular weight
5135.9 Da
Half-life
Approximately 26–38 minutes following subcutaneous injection; the short plasma half-life necessitates daily dosing, though the pharmacodynamic effects on GH pulsatility persist well beyond the peptide's plasma residence time due to downstream pituitary and hepatic signalling cascades.
Category
Growth Hormone Secretagogues
Overview
Tesamorelin is a synthetic 44-amino acid analogue of endogenous human growth hormone-releasing hormone (GHRH), which is itself a 44-amino acid hypothalamic neuropeptide that stimulates pulsatile growth hormone secretion from the anterior pituitary. Tesamorelin differs from native GHRH(1-44) by a single trans-3-hexenoic acid modification at the N-terminus, which confers enhanced plasma stability by protecting the peptide from dipeptidyl peptidase-4 cleavage—the primary mechanism of native GHRH degradation—while preserving full GHRH receptor binding affinity and agonist activity.
Tesamorelin was developed by Theratechnologies Inc., a Canadian biopharmaceutical company, primarily for the treatment of excess visceral adipose tissue accumulation associated with HIV infection and antiretroviral therapy—a condition known as HIV-associated lipodystrophy (HAL). This condition, characterised by preferential visceral fat accumulation with or without peripheral lipoatrophy, produces a metabolic phenotype with elevated cardiovascular and metabolic risk.
The compound received US FDA approval in 2010 under the brand name Egrifta for the treatment of HIV-associated lipodystrophy, making it the only GHRH analogue to have achieved regulatory approval for any therapeutic indication. European regulatory development did not achieve full EMA approval, and in the UK tesamorelin is not approved by the MHRA for any indication—it is accordingly framed in UK research contexts as a research compound.
Research interest in tesamorelin extends beyond HIV lipodystrophy to broader applications in visceral adiposity, metabolic syndrome, and cognitive function research. The compound's mechanism—stimulating pulsatile, physiological growth hormone secretion rather than providing supraphysiological exogenous GH—is hypothesised to offer a more physiologically appropriate and potentially safer approach to GH-axis modulation than direct growth hormone administration.
Discovery & Research History
Tesamorelin's development emerged from Theratechnologies' research programme investigating GHRH analogues in the late 1990s and early 2000s, prompted by the clinical problem of HIV-associated lipodystrophy that had become prominent as combination antiretroviral therapy (cART) dramatically improved HIV survival.
The hypothesis underpinning the tesamorelin programme was that relative growth hormone deficiency played a mechanistic role in the visceral fat accumulation characteristic of HIV lipodystrophy. Evidence supporting this hypothesis included observations of suppressed GH pulsatility in HIV-infected individuals on antiretroviral therapy, and the known lipolytic effects of GH axis activation in visceral adipose tissue. By stimulating endogenous pulsatile GH secretion rather than administering exogenous GH—which would suppress the hypothalamo-pituitary axis and carry diabetogenic risk—GHRH receptor agonism was hypothesised to restore more physiological GH pulsatility.
The selection of trans-3-hexenoic acid as the N-terminal modification reflected the need for DPP-4 resistance without compromising GHRH receptor agonism. Earlier GHRH analogues had used D-alanine substitutions for DPP-4 resistance; Theratechnologies' medicinal chemistry team identified the trans-3-hexenoic acid modification as producing superior plasma stability while maintaining binding affinity comparable to native GHRH in pituitary cell assays.
Phase 2 trials in HIV-infected individuals with excess abdominal fat demonstrated significant reductions in visceral adipose tissue by CT imaging, with improvements in trunk:limb fat ratios and lipid profiles. These results supported the Phase 3 LIPO-010A and LIPO-010B trials, whose combined data supported the FDA submission and 2010 approval of Egrifta.
A reformulated product (Egrifta SV, 2 mg/0.36 mL) received FDA approval in 2019, offering improved convenience over the original formulation. Research programmes investigating tesamorelin in non-HIV populations—including metabolic syndrome, mild cognitive impairment, and non-alcoholic fatty liver disease—have been conducted or are ongoing, leveraging the established safety database from the HIV lipodystrophy programme.
Mechanism of Action
Tesamorelin restores metabolic homeostasis through physiological stimulation of the growth hormone axis, employing mechanisms distinct from direct GH administration:
GHRH Receptor Agonism and Pulsatile GH Release
Tesamorelin binds with high affinity to GHRH receptors on somatotroph cells of the anterior pituitary, activating adenylyl cyclase via Gsα coupling. The resulting cAMP elevation stimulates both GH synthesis and secretion. Critically, tesamorelin preserves the pulsatile character of endogenous GH release—administering the peptide produces GH pulses that mimic the physiological pattern regulated by hypothalamic GHRH and somatostatin, rather than the sustained supraphysiological GH elevation produced by exogenous GH injection. This pulsatile pattern is important because GH receptor downstream signalling, including IGF-1 production and metabolic effects, is regulated by the frequency and amplitude of GH pulses.
Growth Hormone-Mediated Visceral Lipolysis
The GH released in response to tesamorelin acts on GH receptors in visceral adipose tissue to activate hormone-sensitive lipase and stimulate lipolysis. Visceral fat depots express higher densities of GH receptors than subcutaneous adipose depots, which may explain the preferential visceral fat reduction observed clinically. The GH-mediated lipolytic signal in visceral fat operates through a pathway distinct from beta-adrenergic or insulin signalling, involving direct GH receptor–JAK2 activation of HSL.
IGF-1 Stimulation
Unlike the C-terminal hGH fragments (AOD-9604, HGH Fragment 176-191), tesamorelin produces physiological increases in circulating IGF-1 via hepatic GH receptor activation. These increases are within the normal physiological range in clinical studies—not the supraphysiological elevations associated with exogenous GH abuse—and are considered part of the normal GH axis response. The IGF-1 elevation at physiological levels contributes to the lean-mass-sparing effect observed in lipodystrophy trials.
Hypothalamo-Pituitary Axis Preservation
Because tesamorelin acts at the GHRH receptor rather than injecting GH directly, it preserves the normal somatostatin-mediated feedback regulation of GH secretion. Somatostatin released from the hypothalamus in response to elevated IGF-1 and GH acts to moderate the pituitary response, preventing runaway GH excess. This negative feedback loop is absent with exogenous GH administration and is a key pharmacological safety advantage of GHRH receptor agonism.
Lipid and Metabolic Parameter Effects
Beyond direct lipolysis, GH axis activation by tesamorelin produces improvements in triglyceride metabolism through hepatic effects on VLDL synthesis and lipoprotein lipase activity. Reductions in triglycerides, non-HDL cholesterol, and the triglyceride:HDL ratio are observed in clinical populations, consistent with the known roles of GH in hepatic lipid metabolism.
Cognitive and Neurological Effects
GH and IGF-1 receptors are expressed in hippocampal and cortical neurons, where they modulate synaptic plasticity, neurogenesis, and cerebral glucose metabolism. Research in mild cognitive impairment populations has investigated whether tesamorelin-induced GH/IGF-1 elevation improves cognitive test performance, with exploratory data suggesting modest beneficial effects on specific cognitive domains in older adults with mild cognitive impairment.
Researched Effects
- Significant reductions in visceral adipose tissue (VAT) measured by CT imaging in HIV-associated lipodystrophy — mean reductions of approximately 15–20% from baseline in randomised controlled trials.
- Improvements in waist circumference, trunk:limb fat ratio, and patient-reported body image in lipodystrophy populations.
- Reductions in fasting triglycerides and improvements in non-HDL cholesterol in HIV-infected participants with lipodystrophy and dyslipidaemia.
- Preservation of lean body mass relative to fat reduction, consistent with the anabolic and lipolytic balance of physiological GH axis stimulation.
- Physiological increases in serum IGF-1 within normal age-adjusted reference ranges, without the supraphysiological elevations associated with exogenous GH abuse.
- Exploratory evidence of improved cognitive function (executive function, visuospatial processing) in mild cognitive impairment research, investigated in the TRIUMPHANT-AD programme.
- Reductions in hepatic triglyceride content in non-alcoholic fatty liver research, consistent with GH-mediated enhancement of hepatic lipid oxidation.
- Improvements in physical function and fatigue scores in HIV lipodystrophy participants following VAT reduction.
Theoretical Research Protocols
- Dosage range
- FDA-approved Egrifta dose: 2 mg/day subcutaneous injection; research protocols in non-HIV populations have used 1 mg and 2 mg daily; cognitive impairment research used 1 mg nightly
- Frequency
- Once daily subcutaneous injection; nightly administration preferred in some research protocols to coincide with nocturnal GH pulsatility
- Duration
- LIPO trials: 26–52 week primary endpoints with extension studies; cognitive research: 20-week treatment periods; clinical experience extends to 104 weeks in some extension studies
- Administration routes
- Subcutaneous injection — the sole route used in all registrational and research trials; administered daily into the abdomen
Safety Profile
Common side effects (research)
- Injection-site reactions including erythema, pruritus, bruising, and mild induration — the most commonly reported adverse events across LIPO trial populations
- Peripheral oedema — reflecting GH-mediated sodium and water retention; reported in approximately 6–8% of participants in Phase 3 trials
- Arthralgia and myalgia — GH-class effects related to fluid shifts and receptor activation in musculoskeletal tissue; reported in approximately 7–10%
- Carpal tunnel syndrome symptoms — a known GH-class adverse effect; reported at low rates in LIPO programme data
- Nausea and abdominal discomfort — reported at low frequency across trial populations
Rare risks
- Glucose intolerance and diabetes risk — GH axis stimulation can impair insulin sensitivity; monitoring of fasting glucose and HbA1c required in clinical research settings; observed in a small proportion of LIPO participants
- Progression of malignant neoplasms — GH and IGF-1 elevation may theoretically promote growth in existing tumours; a class-level concern requiring appropriate participant selection in research programmes
- Hypersensitivity reactions including anaphylaxis — uncommon but reported; relevant given the peptide's foreign sequence relative to native GHRH
- Hypothyroidism — GH axis activation can alter thyroid hormone levels; thyroid function monitoring is recommended in prolonged research programmes
- Fluid retention-related cardiovascular effects at high doses or in predisposed individuals
Contraindications
- Active malignancy or history of malignancy — GH and IGF-1 elevation contraindicated given theoretical tumour-promotion risk
- Disruption of hypothalamo-pituitary axis from any cause, including cranial irradiation, pituitary tumour, or trauma (tesamorelin requires functional pituitary somatotrophs for effect)
- Pregnancy and breastfeeding — IGF-1 elevation during pregnancy is not appropriate; no clinical safety data
- Severe hepatic impairment — pharmacokinetic data limited
- Hypersensitivity to tesamorelin, GHRH, or any excipient of the research preparation
UK Regulatory Status
United Kingdom (MHRA): Tesamorelin is not approved by the MHRA for any therapeutic indication in the UK. It is not a licensed medicine under the Human Medicines Regulations 2012. The FDA-approved Egrifta (US indication: HIV-associated lipodystrophy) does not confer any UK or EU marketing authorisation. In the UK, tesamorelin may be used only as a research compound for preclinical or in vitro investigation under appropriate institutional governance, or within a formally authorised clinical trial holding a Clinical Trial Authorisation (CTA). Its supply for unlicensed human use is not permitted.
European Union (EMA): Tesamorelin is not authorised by the EMA for any indication. EMA's centralised procedure assessment of tesamorelin for HIV lipodystrophy did not result in marketing authorisation in the EU. Research compound status applies across all EU member states.
Notes: Tesamorelin is the only GHRH receptor agonist to have achieved regulatory approval (FDA, US only) for any therapeutic indication, providing a uniquely characterised clinical safety database among GHRH analogues. This clinical precedent does not confer UK or EU approval. WADA lists GHRH-class peptides as prohibited substances in competitive sport; tesamorelin is accordingly prohibited.
Related research resources
Key Research Studies
LIPO-010A: Tesamorelin in HIV-Infected Patients with Abdominal Fat Accumulation
A 26-week randomised, double-blind, placebo-controlled Phase 3 trial enrolling 412 HIV-infected adults with abdominal fat accumulation on antiretroviral therapy. Tesamorelin 2 mg/day produced a mean reduction in visceral adipose tissue (VAT) of 15.2% versus a 5.0% increase with placebo (treatment difference −20.2%). Significant improvements in waist circumference, trunk:limb fat ratio, and triglycerides were observed. The safety profile was consistent with Phase 2 data.
Read sourceLIPO-010B: Confirmatory Phase 3 Trial of Tesamorelin in HIV Lipodystrophy
A 26-week parallel randomised confirmatory trial enrolled 404 HIV-infected adults with excess abdominal fat. Results corroborated LIPO-010A: tesamorelin 2 mg/day produced mean VAT reduction of 18.1% versus 2.6% increase with placebo. The combined LIPO-010A and LIPO-010B data package supported the 2010 FDA approval of Egrifta. Maintenance of VAT reduction at 52 weeks was demonstrated in the extension phase.
Tesamorelin in Adults with Mild Cognitive Impairment and Healthy Older Adults
A 20-week randomised, placebo-controlled trial investigating tesamorelin 1 mg nightly in 152 adults with mild cognitive impairment (MCI) and older healthy adults. Tesamorelin produced significant increases in IGF-1 within physiological reference ranges and showed directional improvement in executive function and visuospatial processing test scores in MCI participants. Mechanistic analyses suggested effects on regional brain metabolism by 18F-FDG PET imaging, supporting ongoing investigation in the TRIUMPHANT-AD programme.
Long-term Safety of Tesamorelin: 52-week and Extension Data
Integrated safety analyses across the LIPO trials and their 52-week extensions characterised the long-term adverse event profile of daily tesamorelin in HIV-infected populations. Peripheral oedema, arthralgia, and injection-site reactions remained the most common events. Glucose tolerance impairment occurred in a small proportion of participants and required discontinuation in some. No significant increase in malignancy incidence was observed over the follow-up period, though the populations were not powered for this endpoint.
Frequently Asked Questions
What is tesamorelin and how does it differ from growth hormone itself?
Tesamorelin is a synthetic GHRH analogue that stimulates the pituitary to produce its own growth hormone in pulsatile fashion, rather than directly administering exogenous GH. This distinction is important: endogenous pulsatile GH release preserves normal somatostatin-mediated feedback regulation, maintaining IGF-1 within physiological ranges and avoiding the runaway GH excess, insulin resistance, and acromegalic effects associated with supraphysiological exogenous GH administration.
What condition is tesamorelin approved for, and by which authority?
Tesamorelin (Egrifta) is approved by the US FDA for the treatment of excess visceral abdominal fat in HIV-infected adults with lipodystrophy. This is its sole approved indication globally. It is not approved by the MHRA (UK), the EMA (EU), or any other regulatory authority outside the United States for any indication. In the UK it is classified as a research compound.
Is tesamorelin being studied for conditions other than HIV lipodystrophy?
Yes. Research programmes have investigated tesamorelin in: metabolic syndrome and abdominal obesity in HIV-negative individuals; mild cognitive impairment and early Alzheimer's disease (TRIUMPHANT-AD programme), based on GH/IGF-1's roles in hippocampal neuroplasticity; non-alcoholic fatty liver disease, given GH's known effects on hepatic lipid metabolism; and age-related GH deficiency. These studies leverage the established safety database from the HIV lipodystrophy programme.
Does tesamorelin affect blood sugar or insulin levels?
Yes. GH axis stimulation by tesamorelin can impair insulin sensitivity through classic GH counter-regulatory effects on glucose uptake. In LIPO trial populations, a small proportion of participants developed glucose intolerance requiring monitoring and in some cases discontinuation. Fasting glucose and HbA1c monitoring are standard in clinical research protocols using tesamorelin. The magnitude of glucose impairment is generally less than seen with exogenous GH administration, consistent with the lower and more physiologically regulated IGF-1 elevations produced.
What is the regulatory status of tesamorelin for research in the UK?
Tesamorelin is not approved by the MHRA for any indication in the UK. It is a research compound that may be procured for preclinical or in vitro investigation under appropriate institutional governance, or studied in humans only within a formally authorised clinical trial with a Clinical Trial Authorisation (CTA). Supply for unlicensed human therapeutic use is not permitted under the Human Medicines Regulations 2012. GHRH-class peptides are prohibited by WADA.
How is tesamorelin administered and what is its half-life?
Tesamorelin is administered via once-daily subcutaneous injection, typically into the abdominal region. Its plasma half-life is approximately 26–38 minutes — much shorter than semaglutide or tirzepatide — reflecting its mechanism of action as a pulsatile stimulus rather than a sustained receptor occupant. The pharmacodynamic effects on GH pulsatility persist well beyond this short plasma half-life through downstream pituitary signalling, and daily dosing is sufficient to maintain significant VAT reduction in clinical research.
Licensed brand-name medicines
Related trials
No published trials yet linked to this page. Source verification required.